Show simple item record

dc.contributor.authorBartlett, J. M. S.
dc.contributor.authorStarczynski, J.
dc.contributor.authorAtkey, N.
dc.contributor.authorKay, E.
dc.contributor.authorO'Grady, A.
dc.contributor.authorGandy, M.
dc.contributor.authorIbrahim, M.
dc.contributor.authorJasani, B.
dc.contributor.authorEllis, I. O.
dc.contributor.authorPinder, S. E.
dc.contributor.authorWalker, R. A.
dc.date.accessioned2012-06-20T14:11:17Z
dc.date.available2012-06-20T14:11:17Z
dc.date.issued2011
dc.identifier.citationHER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods 2011, 64 (8):649 Journal of Clinical Pathologyen_GB
dc.identifier.issn0021-9746
dc.identifier.doi10.1136/jcp.2011.089847
dc.identifier.urihttp://hdl.handle.net/10147/229951
dc.description.abstractThese guidelines supplement existing guidelines on HER2 testing by immunohistochemistry and in-situ hybridisation(ISH) methods in the UK. They provide a specific focus on aspects of guidance relevant to HER2 ISH testing methods, both fluorescent and chromogenic. They are formulated to give advice on methodology, interpretation and quality control for ISH-based testing of HER2 status in common tumour types, including both breast and gastric tumours. The aim is to ensure that all ISH-based testing is accurate, reliable and timely.
dc.language.isoenen
dc.relation.urlhttp://jcp.bmj.com/cgi/doi/10.1136/jcp.2011.089847en_GB
dc.rightsArchived with thanks to Journal of Clinical Pathologyen_GB
dc.titleHER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methodsen_GB
dc.typeArticleen
dc.identifier.journalJournal of Clinical Pathologyen_GB
dc.description.provinceLeinsteren
html.description.abstractThese guidelines supplement existing guidelines on HER2 testing by immunohistochemistry and in-situ hybridisation(ISH) methods in the UK. They provide a specific focus on aspects of guidance relevant to HER2 ISH testing methods, both fluorescent and chromogenic. They are formulated to give advice on methodology, interpretation and quality control for ISH-based testing of HER2 status in common tumour types, including both breast and gastric tumours. The aim is to ensure that all ISH-based testing is accurate, reliable and timely.


This item appears in the following Collection(s)

Show simple item record